Disclosure of Financial Relationships with Commercial ...2020.pas- ... Disclosure of Financial...

download Disclosure of Financial Relationships with Commercial ...2020.pas- ... Disclosure of Financial Relationships

of 31

  • date post

    07-Oct-2020
  • Category

    Documents

  • view

    0
  • download

    0

Embed Size (px)

Transcript of Disclosure of Financial Relationships with Commercial ...2020.pas- ... Disclosure of Financial...

  • Disclosure of Financial Relationships with Commercial Interests

    * Presenter # Moderator † SIG Chair ‡ Session Chair ¥ Planner-Owner ¤ Workshop Leader Δ Operating Committee ᴧ Program Committee § PAS Staff

    1

    Disclosure Policy

    Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CME activities that are scientifically based, accurate, current, and objectively presented.

    In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships: 1) at the time of the activity or within 12 months prior; and 2) of their spouses/partners.

    In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME’s validation of clinical content statements.

    BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

    Drug/Device Status Disclosure Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with applicable law. Baylor College of Medicine requires that all faculty/presenters disclose an unlabeled use or investigational use of pharmaceutical and medical device products, and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.

    Presenters Disclosures – Financial Relationships

    The following faculty/presenters/conference moderators have reported that she/he has/had financial relationships with commercial interests (drug/device companies):

    Abman, Steven*‡ Yes - Financial Interest; Shire:Grant/Research Support (including support for clinical trials)|Shire:Consultancy|United Therapeutics:Grant/Research Support (including support for clinical trials)

    Abuabara, Katrina* Yes - Financial Interest; TARGET Pharma:Consultancy Abuzzahab, Mary* Yes - Financial Interest; Ascendis:Grant/Research Support (including support for clinical

    trials)|Soleno:Grant/Research Support (including support for clinical trials)|AstraZeneca:Grant/Research Support (including support for clinical trials)|NovoNordisk:

    Ackerman, Kate*# Yes - Financial Interest; ONYBiotech:Consultancy Adi, Saleh‡ Yes - Financial Interest; Dexcom:Speakers Bureau Membership|Dexcom:Ownership Interests (stock or

    stock options; excluding diversified mutual funds)|Dexcom:Honorarium Recipient|Tandem Diabetes Care:Ownership Interests (stock or stock options; excluding div

    Akers, Aletha*¤ Yes - Financial Interest; Bayer Healthcare:Grant/Research Support (including support for clinical trials)|Templeton Foundation:Grant/Research Support (including support for clinical trials)|Merck Inc:Advisory Committee Membership|Women's Way:Board Members

    Albertine, KH* Yes - Financial Interest; Shire Pharmaceutical:Grant/Research Support (including support for clinical trials)|United Therapeutic:Grant/Research Support (including support for clinical trials)

    Aligne, C* Yes - Financial Interest; Merck:Speakers Bureau Membership Ambalavanan, Namasivayam*

    Yes - Financial Interest; SHIRE:Advisory Committee Membership

    Anderson, Larry* Yes - Financial Interest; Bavarian Nordic:Consultancy|Phizer:Grant/Research Support (including support for clinical trials)|Novavax:Consultancy|Daiichi-Sankyo:Consultancy

  • Disclosure of Financial Relationships with Commercial Interests

    * Presenter # Moderator † SIG Chair ‡ Session Chair ¥ Planner-Owner ¤ Workshop Leader Δ Operating Committee ᴧ Program Committee § PAS Staff

    2

    Anderson, Marsha¥ᴧ Yes - Financial Interest; American Psychiatric Press/Journal of Neuropsychiatry (Spouse):Advisory Committee Membership|Cambridge University Press (Spouse):Intellectual Property (patent rights, royalty payments)|Bayer Corporation (Spouse):Grant/Research Su

    Andrews, Bree*¤ Yes - Financial Interest; Preeme+You:Advisory Committee Membership Antommaria, Armand# Yes - Financial Interest; Amicus Therapeutics :Consultancy Arai, Katsuhiro¥ᴧ Yes - Financial Interest; Nippon Kayaku CO., LTD:Grant/Research Support (including support for clinical

    trials)|Mitsubishi Tanabe Pharma Corporation:Honorarium Recipient|EA Pharma CO., LTD:Honorarium Recipient|Kyorin Pharmaceutical CO., LTD:Honorarium Rec

    Armstrong, Aimee* Yes - Financial Interest; Abbott:Consultancy Arslanian, Silva* Yes - Financial Interest; Eli Lilly and Co.:Grant/Research Support (including support for clinical trials)|Novo

    Nordisk:Grant/Research Support (including support for clinical trials)|Boehringer-Ingelheim:Board Membership|Astra Zeneca:Board Membership

    Aschner, Judy*#‡ Yes - Financial Interest; shire pharmaceuticals:Consultancy|gilead:Ownership Interests (stock or stock options; excluding diversified mutual funds)

    Ashok, Dhandapani* Yes - Financial Interest; Alexion Pharma:Honorarium Recipient|Abbvie Pharma:Honorarium Recipient|Janssen Canada:Honorarium Recipient

    Ashraf, Ambika* Yes - Financial Interest; Opko:Grant/Research Support (including support for clinical trials)|Ultragenyx:Speakers Bureau Membership|Pfizer:Speakers Bureau Membership|Bristol Mayer Squibb:Speakers Bureau Membership|Celgene:Speakers Bureau Membership|Insys

    Askenazi, David* Yes - Financial Interest; baxter:Speakers Bureau Membership|aki foundation:Speakers Bureau Membership

    Asselin, Jeanette* Yes - Financial Interest; AerogenPharma:Employment Atkinson, Meredith* Yes - Financial Interest; AstraZeneca:Employment Axelrod, David* Yes - Financial Interest; Lighthaus Inc.:Ownership Interests (stock or stock options; excluding diversified

    mutual funds) Bachrach, Laura‡ Yes - Financial Interest; Myovant:Consultancy Backeljauw, Philippe* Yes - Financial Interest; Novo Nordisk:Grant/Research Support (including support for clinical

    trials)|Ipsen:Grant/Research Support (including support for clinical trials)|Opko:Grant/Research Support (including support for clinical trials)|Sandoz:Grant/Res

    Bailey, Michael* Yes - Financial Interest; Scioto Biosciences:Ownership Interests (stock or stock options; excluding diversified mutual funds)

    Bancalari, Eduardo* Yes - Financial Interest; Vyaire:Intellectual Property (patent rights, royalty payments)|Vyaire:Grant/Research Support (including support for clinical trials)

    Bateman, Brian* Yes - Financial Interest; Aetion:Consultancy|Alosa:Consultancy|Baxalta:Grant/Research Support (including support for clinical trials)|Lilly:Grant/Research Support (including support for clinical trials)|GSK:Grant/Research Support (including support for cl

    Baum, Michelle A.* Yes - Financial Interest; Retrophin:Advisory Committee Membership|Dicerna:Advisory Committee Membership

    Beidas, Rinad* Yes - Financial Interest; Oxford University Press:Intellectual Property (patent rights, royalty payments)|Camden Coalition of Healthcare Providers:Consultancy

    Benfield, Mark‡ Yes - Financial Interest; Mallinckrodt:Grant/Research Support (including support for clinical trials)|Mallinckrodt:Speakers Bureau Membership|Horizon:Speakers Bureau Membership

    Bennett, Amanda* Yes - Financial Interest; Autism Speaks:Grant/Research Support (including support for clinical trials)|Stemina Biomarker Discovery:Grant/Research Support (including support for clinical trials)|Neurim Pharmaceuticals:Grant/Research Support (including supp

    Bennett, Kevin* Yes - Financial Interest; Sindri Technologies:Intellectual Property (patent rights, royalty payments)|Nephrodiagnostics LLC:Intellectual Property (patent rights, royalty payments)

    Benz, Lisa*† Yes - Financial Interest; LSI:Employment|Halyard Health:Employment Berman, Darren* Yes - Financial Interest; Medtronic:Consultancy|Edwards Life Sciences:Consultancy|Abbott:Consultancy Bernstein, Daniel* Yes - Financial Interest; Regencor:Ownership Interests (stock or stock options; excluding diversified mutual

    funds) Beukelman, Timothy* Yes - Financial Interest; UCB:Consultancy|Novartis:Consultancy Biniwale, Manoj*¤ Yes - Financial Interest; Chiesi Farmace